Company Overview and News

 
Singapore shares decline at Friday's open; STI down 0.55% to 3,052.84

2018-10-19 businesstimes.com.sg
SINGAPORE stocks opened weaker on Friday, with the Straits Times Index declining 0.55 per cent or 16.83 points to 3,052.84 as at 9.03am after overnight declines in US markets.
SO7 UOVEF DBSDY BLVW AIQW U11 YSHLF D05 DBSDF UOVEY AMIW AMJW BS6

 
UOB launches eLab to personalise digital services

2018-10-19 businesstimes.com.sg
UNITED Overseas Bank (UOB) on Thursday launched a pan-regional Engagement Lab (eLab) to personalise the way in which it converses with and serves customers of its upcoming Digital Bank services.
UOVEF UOVEY U11

 
UOB launches eLab for upcoming Digital Bank; hiring 60 more for digital banking team

2018-10-18 businesstimes.com.sg
UNITED Overseas Bank (UOB) on Thursday launched a pan-regional Engagement Lab (eLab) to to personalise the way in which it converses and serves customers of its upcoming Digital Bank services.
UOVEF UOVEY U11

 
Temasek's 2.7% bond expected to attract retail investors

2018-10-17 businesstimes.com.sg
WITH Temasek Holdings' 2.7 per cent five-year bond having been heavily subscribed by institutional investors, bets are on that retail demand for this public bond offer, which opened on Wednesday, will be hot as well.
UOVEF UOVEY U11

 
STI generates -7.4% returns YTD, 12.9% over 3 years

2018-10-17 businesstimes.com.sg
THE Straits Times Index (STI) has generated a total return of -7.4 per cent for investors from January to Oct 15, according to a Singapore Exchange (SGX) update on Tuesday.
GARPY SPXCY E5H UOVEF CPAMF SGPRY GARPF SPXCF UOVEY SGPRF U11 S68

 
Singapore shares rise at Wednesday's open; STI up 1.61% to 3,083.05

2018-10-17 businesstimes.com.sg
SINGAPORE stocks opened higher on Wednesday, with the Straits Times Index gaining 1.61 per cent or 48.74 points to 3,083.05 as at 9.02am after US stocks rebounded overnight.
UOVEF DBSDY D05 DBSDF UOVEY 5WH U11

 
Will the yuan deteriorate past 7 per dollar? Don’t bet on it happening any time soon, survey shows

2018-10-15 scmp
China is unlikely to let the yuan weaken past the key psychological level of 7 per dollar any time soon, according to market observers.
UOVEF STAN MLYBY MLYNF U11 1155 3968 580001 STAB STAN STAC 2888 SCBFF UOVEY

 
Singapore shares decline at Monday's open; STI down 0.27% to 3,060.95

2018-10-15 businesstimes.com.sg
SINGAPORE stocks opened weaker on Monday, with the Straits Times Index moving down 0.27 per cent or 8.22 points to 3,060.95 as at 9.02am.
UOVEF UOVEY JDSHF JSHLY U11 KI3

 
UOB reviewing insurance deal with Prudential

2018-10-13 thestar.com.my
HONG KONG: Singapore lender United Overseas Bank Ltd (UOB) is reviewing its insurance business, including an existing partnership with Prudential Plc, after South-East Asia witnessed a wave of lucrative distribution deals, sources said.
UOVEF STAN ALIZF PBCRY U13 U11 AAIGF PUK 580001 STAB STAN STAC 2888 UOVEY SCBFF AAGIY AZSEY PUKPF PBCRF

 
Singapore's UOB is said to review insurance deal with Prudential

2018-10-11 theedgemarkets
(Oct 11): Singapore lender United Overseas Bank Ltd is reviewing its insurance business, including an existing partnership with Prudential Plc, after Southeast Asia witnessed a wave of lucrative distribution deals, people familiar with the matter said.
UOVEF STAN ALIZF U13 U11 PUK 580001 STAB STAN STAC 2888 UOVEY SCBFF AZSEY PUKPF

 
UOB reviewing insurance deal with Prudential

2018-10-11 thestar.com.my
SINGAPORE: United Overseas Bank Ltd is reviewing its insurance business, including an existing partnership with Prudential Plc, after Southeast Asia witnessed a wave of lucrative distribution deals, people familiar with the matter said.
UOVEF STAN ALIZF U13 U11 PUK 580001 STAB STAN STAC 2888 UOVEY SCBFF AZSEY PUKPF

 
The State of the Nation: A crude oil comeback for real?

2018-10-08 theedgemarkets
Rising crude oil prices are seen as a positive for Putrajaya as they help ease the financial risks and mitigate uncertainties over revenue collection
UOVEF UOVEY U11

 
Singapore stocks: STI resumes Monday afternoon at 3,194.38, down 0.48% on day

2018-10-08 businesstimes.com.sg
SINGAPORE stocks fell on Monday afternoon's trading resumption, with the Straits Times Index declining 15.41 points or 0.48 per cent on the day to 3,194.38 as at 1.01pm.
5TY NCMHF UOVEF DBSDY D05 N4E DBSDF UOVEY U11

 
Hong Kong's economy gets stuck between U.S.-China trade war

2018-10-05 theedgemarkets
Hong Kong has long marketed itself as the gateway into China for foreign businesses, especially the U.S. With a trade war now raging between the world’s two largest economies, that’s precisely the problem.
UOVEF UOVEY U11

 
UOB and NTUC launch digital innovation awards programme for SMEs

2018-10-05 theedgemarkets
SINGAPORE (Oct 5): United Overseas Bank (UOB) and labour movement initiative NTUC U SME on Wednesday launched the SME Digital Leap Awards at the Winning in the Digital Economy for SMEs event, which saw the attendance of more than 200 SMEs.
UOVEF UOVEY U11

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: V96194127